Targeted Inhibition of FAK, PYK2 and BCL-XL Synergistically Enhances Apoptosis in Ovarian Clear Cell Carcinoma Cell Lines

Ovarian clear cell carcinoma (OCCC) displays a higher resistance to first line chemotherapy, requiring the development of new therapeutics. We previously identified a frequent chromosomal gain at 8q24 that harbors the focal-adhesion kinase (FAK) gene; the potential of this gene as a therapeutic target remains to be evaluated in OCCCs. We first examined the dependence of OCCCs on FAK and the PI3K/AKT signaling pathway. FAK was overexpressed in 20% of 67 OCCC samples, and this overexpression was correlated with its copy number gain. FAK copy number gains and mutations in PIK3CA accounted for about 40% of OCCC samples, suggesting that the FAK/PI3K/AKT axis is an attractive candidate for targeted therapeutics. We, therefore, treated ovarian cancer cell lines, including OCCC subtypes, with the FAK inhibitors PF-562,271 (PF271), and PF-573,228 (PF228). Ovarian cancer cells were more sensitive to PF271 than PF228. We then searched for single agents that exhibited a synergistic effect on cell death in combination with PF271. We found that co-treatment of PF271 with ABT-737, a BCL-2/BCL-XL antagonist, was profoundly effective at inducing apoptosis. RMGI and OVISE cells were more sensitive to ABT-737 than OVMANA and SKOV3 cells, which have PIK3CA mutations. Mechanistically, PF271 treatment resulted in the transient down-regulation of the anti-apoptotic protein MCL1 via the PI3K/AKT pathway. Therefore, PF271/ABT-737 treatment led to the inhibition of the anti-apoptotic proteins MCL1 and BCL-XL/BCL-2. We suggest that pharmacological inhibition of BCL-XL and FAK/PYK2 can be a potential therapeutic strategy for the treatment of OCCC.

[1]  S. Grant,et al.  Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. , 2013, Cancer Research.

[2]  M. Birrer,et al.  Clear cell carcinoma of the ovary: a review of the literature. , 2012, Gynecologic oncology.

[3]  Andrew L. Kung,et al.  Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. , 2012, Cancer cell.

[4]  F. Rescorla,et al.  Cell surface adhesion molecules and adhesion-initiated signaling: understanding of anoikis resistance mechanisms and therapeutic opportunities. , 2012, Cellular signalling.

[5]  J. Christensen,et al.  Cooperation between c-Met and Focal Adhesion Kinase Family Members in Medulloblastoma and Implications for Therapy , 2011, Molecular Cancer Therapeutics.

[6]  Yonghong Xiao,et al.  SCFFBW 7 regulates cellular apoptosis by targeting MCL 1 for ubiquitylation and destruction , 2011 .

[7]  Richard A. Moore,et al.  ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.

[8]  Tian-Li Wang,et al.  Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.

[9]  W. Fiedler,et al.  Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer , 2010, Expert opinion on investigational drugs.

[10]  Derek W. Yecies,et al.  Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. , 2010, Blood.

[11]  L. Poulain,et al.  Bcl‐XL and MCL‐1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis , 2009, International journal of cancer.

[12]  V. Tron,et al.  RNA Silencing of Mcl-1 Enhances ABT-737-Mediated Apoptosis in Melanoma: Role for a Caspase-8-Dependent Pathway , 2009, PloS one.

[13]  A. Aplin,et al.  Mcl-1 Is Required for Melanoma Cell Resistance to Anoikis , 2009, Molecular Cancer Research.

[14]  F. Sinicrope,et al.  Induction of Noxa Sensitizes Human Colorectal Cancer Cells Expressing Mcl-1 to the Small-Molecule Bcl-2/Bcl-xL Inhibitor, ABT-737 , 2008, Clinical Cancer Research.

[15]  Matthew D. Wessel,et al.  Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. , 2008, Cancer research.

[16]  T. Tsuruo,et al.  β1 integrin/Fak/Src signaling in intestinal epithelial crypt cell survival: integration of complex regulatory mechanisms , 2008, Apoptosis.

[17]  H. Yamaguchi,et al.  Anoikis, initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesis. , 2007, Cancer research.

[18]  Christopher Autry,et al.  Cellular Characterization of a Novel Focal Adhesion Kinase Inhibitor* , 2007, Journal of Biological Chemistry.

[19]  N. Munshi,et al.  A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma , 2007, Oncogene.

[20]  P. Dent,et al.  Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. , 2007, Cancer research.

[21]  John Calvin Reed,et al.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. , 2006, Cancer cell.

[22]  Liz Y. Han,et al.  Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy , 2006, Clinical Cancer Research.

[23]  D. Green,et al.  Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. , 2006, Molecular cell.

[24]  A. Piché,et al.  Bcl-XL is functionally non-equivalent for the regulation of growth and survival in human ovarian cancer cells , 2006 .

[25]  A. Piché,et al.  Bcl-X(L) is functionally non-equivalent for the regulation of growth and survival in human ovarian cancer cells. , 2006, Gynecologic oncology.

[26]  A. Sood,et al.  Focal Adhesion Kinase Silencing Augments Docetaxel-Mediated Apoptosis in Ovarian Cancer Cells , 2005, Clinical Cancer Research.

[27]  V. Golubovskaya,et al.  Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines , 2005, Melanoma research.

[28]  Neil O. Carragher,et al.  The role of focal-adhesion kinase in cancer — a new therapeutic opportunity , 2005, Nature Reviews Cancer.

[29]  K. Griffith,et al.  Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. , 2005, Gynecologic oncology.

[30]  T. Kasahara,et al.  Down-regulation of procaspase-8 expression by focal adhesion kinase protects HL-60 cells from TRAIL-induced apoptosis. , 2004, Biochemical and biophysical research communications.

[31]  R. Nho,et al.  Focal Adhesion Kinase Is Upstream of Phosphatidylinositol 3-Kinase/Akt in Regulating Fibroblast Survival in Response to Contraction of Type I Collagen Matrices via a β1 Integrin Viability Signaling Pathway* , 2004, Journal of Biological Chemistry.

[32]  R. Craig,et al.  MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol , 2004, Oncogene.

[33]  S. Hanks,et al.  Focal Adhesion Kinase Suppresses Apoptosis by Binding to the Death Domain of Receptor-Interacting Protein , 2004, Molecular and Cellular Biology.

[34]  V. Golubovskaya,et al.  Simultaneous inhibition of focal adhesion kinase and SRC enhances detachment and apoptosis in colon cancer cell lines. , 2003, Molecular cancer research : MCR.

[35]  Wenhua Gao,et al.  Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. , 2003, Genes & development.

[36]  V. Golubovskaya,et al.  Dual Inhibition of Focal Adhesion Kinase and Epidermal Growth Factor Receptor Pathways Cooperatively Induces Death Receptor-mediated Apoptosis in Human Breast Cancer Cells* , 2002, The Journal of Biological Chemistry.

[37]  O. Katoh,et al.  Increased MCL–1 Expression Is Associated with Poor Prognosis in Ovarian Carcinomas , 2002, Japanese journal of cancer research : Gann.

[38]  V. Litvak,et al.  Targeting of PYK2 to Focal Adhesions as a Cellular Mechanism for Convergence between Integrins and G Protein-coupled Receptor Signaling Cascades* , 2000, The Journal of Biological Chemistry.

[39]  D. Brenner,et al.  The Focal Adhesion Kinase Suppresses Transformation-associated, Anchorage-independent Apoptosis in Human Breast Cancer Cells , 2000, The Journal of Biological Chemistry.

[40]  B K Slinker,et al.  The statistics of synergism. , 1998, Journal of molecular and cellular cardiology.